JP2010518061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518061A5 JP2010518061A5 JP2009548738A JP2009548738A JP2010518061A5 JP 2010518061 A5 JP2010518061 A5 JP 2010518061A5 JP 2009548738 A JP2009548738 A JP 2009548738A JP 2009548738 A JP2009548738 A JP 2009548738A JP 2010518061 A5 JP2010518061 A5 JP 2010518061A5
- Authority
- JP
- Japan
- Prior art keywords
- salt according
- salt
- oxazol
- ylmethyl
- benzyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- STTGOFBGRUQUOE-NDEPHWFRSA-N 2-[(4-chlorophenyl)methoxy]ethyl-[[2-[(R)-cyclohexyl-hydroxy-phenylmethyl]-1,3-oxazol-5-yl]methyl]-dimethylazanium Chemical compound C=1N=C([C@@](O)(C2CCCCC2)C=2C=CC=CC=2)OC=1C[N+](C)(C)CCOCC1=CC=C(Cl)C=C1 STTGOFBGRUQUOE-NDEPHWFRSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (9)
- [２−(４−クロロ−ベンジルオキシ)−エチル]−[２−((Ｒ)−シクロヘキシル−ヒドロキシ−フェニル−メチル)−オキサゾール−５−イルメチル]−ジメチル−アンモニウムナパジシル酸塩。
- [２−(４−クロロ−ベンジルオキシ)−エチル]−[２−((Ｒ)−シクロヘキシル−ヒドロキシ−フェニル−メチル)−オキサゾール−５−イルメチル]−ジメチル−アンモニウムヘミ−ナフタレン−１,５−ジスルホン酸塩である、請求項１に記載の塩。
- 少なくとも次の特徴的Ｘ線粉末回折ピーク(２θ度で示す)を示す、請求項２に記載の塩：
５.３、１０.５、１５.８および１６.５、または
５.３、１０.５、１５.８、１６.５、１８.６および１９.４または
５.３、１０.５、１５.８、１６.５、１８.６、１９.４、１９.７および２０.３または
５.３、１０.５、１５.８、１６.５、１７.８、１８.６、１９.４、１９.７、２０.４および２１.７。 - 図１と実質的に同じＸ線粉末回折パターンを有する、請求項３に記載の塩。
- 無水和物である、請求項１〜４のいずれかに記載の塩。
- 請求項１〜５のいずれかに記載の塩を薬学的に許容されるアジュバント、希釈剤または担体と共に含む、医薬組成物。
- 治療において使用するための、請求項１〜５のいずれかに記載の塩。
- 慢性閉塞性肺疾患の処置用医薬の製造における、請求項１〜５のいずれかに記載の塩の使用。
- 慢性閉塞性肺疾患の処置方法であって、請求項１〜５のいずれかに記載の塩をかかる処置を必要とする患者に投与することを含む、方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0702385.6 | 2007-02-07 | ||
| GB0702416.9 | 2007-02-07 | ||
| GBGB0702416.9A GB0702416D0 (en) | 2007-02-07 | 2007-02-07 | New combination |
| GBGB0702385.6A GB0702385D0 (en) | 2007-02-07 | 2007-02-07 | New combination |
| PCT/GB2008/000434 WO2008096149A2 (en) | 2007-02-07 | 2008-02-06 | Napadisylate salt of a muscarinic m3 antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518061A JP2010518061A (ja) | 2010-05-27 |
| JP2010518061A5 true JP2010518061A5 (ja) | 2011-03-10 |
| JP5373634B2 JP5373634B2 (ja) | 2013-12-18 |
Family
ID=39485211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548738A Expired - Fee Related JP5373634B2 (ja) | 2007-02-07 | 2008-02-06 | ムスカリンｍ３アンタゴニストのナパジシル酸塩 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7846955B2 (ja) |
| EP (1) | EP2118078A2 (ja) |
| JP (1) | JP5373634B2 (ja) |
| KR (1) | KR20090119757A (ja) |
| AU (1) | AU2008212673B2 (ja) |
| BR (1) | BRPI0807004A2 (ja) |
| CA (1) | CA2675629A1 (ja) |
| EC (1) | ECSP099566A (ja) |
| IL (1) | IL199909A0 (ja) |
| MX (1) | MX2009008364A (ja) |
| NZ (1) | NZ578475A (ja) |
| RU (1) | RU2459810C2 (ja) |
| WO (1) | WO2008096149A2 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0516313D0 (en) * | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| BRPI0822693A2 (pt) | 2008-05-13 | 2015-07-07 | Astrazeneca Ab | Derivados de quinuclidina como antagonistas do receptor muscarínico m3 |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| US8975310B2 (en) | 2011-07-20 | 2015-03-10 | Brigham Young University | Hydrophobic ceragenin compounds and devices incorporating same |
| RU2669800C2 (ru) | 2013-03-15 | 2018-10-16 | Брихэм Янг Юниверсити | Способы лечения воспаления, аутоиммунных расстройств и боли |
| US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
| US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
| US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
| WO2016172534A1 (en) * | 2015-04-22 | 2016-10-27 | Savage Paul B | Cationic steroidal antimicrobial salts |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
| WO2019073052A1 (en) | 2017-10-13 | 2019-04-18 | Treeway Tw001 B.V. | EDARAVONE SALT |
| US11485567B2 (en) * | 2020-04-09 | 2022-11-01 | Shi Chia Lin Industry Co., Ltd. | Coaxial container for dispensing a tubular product |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733332B2 (ja) * | 1985-11-19 | 1995-04-12 | 富山化学工業株式会社 | 痴呆症状改善・治療剤 |
| EP0307141B1 (en) * | 1987-09-10 | 1993-01-13 | MERCK SHARP & DOHME LTD. | Oxazoles and thiazoles for the treatment of senile dementia |
| GB9603755D0 (en) * | 1996-02-22 | 1996-04-24 | Pfizer Ltd | Therapeutic agents |
| GB0516313D0 (en) * | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| WO2008017827A2 (en) * | 2006-08-08 | 2008-02-14 | Argenta Discovery Limited | Azole and thiazole derivatives and their uses |
-
2008
- 2008-02-06 EP EP08702081A patent/EP2118078A2/en not_active Withdrawn
- 2008-02-06 WO PCT/GB2008/000434 patent/WO2008096149A2/en active Application Filing
- 2008-02-06 JP JP2009548738A patent/JP5373634B2/ja not_active Expired - Fee Related
- 2008-02-06 AU AU2008212673A patent/AU2008212673B2/en not_active Ceased
- 2008-02-06 MX MX2009008364A patent/MX2009008364A/es active IP Right Grant
- 2008-02-06 CA CA002675629A patent/CA2675629A1/en not_active Abandoned
- 2008-02-06 NZ NZ578475A patent/NZ578475A/en not_active IP Right Cessation
- 2008-02-06 US US12/523,172 patent/US7846955B2/en not_active Expired - Fee Related
- 2008-02-06 BR BRPI0807004-0A2A patent/BRPI0807004A2/pt not_active IP Right Cessation
- 2008-02-06 KR KR1020097016486A patent/KR20090119757A/ko not_active Application Discontinuation
- 2008-02-06 RU RU2009133262/04A patent/RU2459810C2/ru not_active IP Right Cessation
-
2009
- 2009-07-16 IL IL199909A patent/IL199909A0/en unknown
- 2009-08-06 EC EC2009009566A patent/ECSP099566A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518061A5 (ja) | ||
| JP2012532874A5 (ja) | ||
| JP2008539268A5 (ja) | ||
| JP2008513510A5 (ja) | ||
| JP2013509429A5 (ja) | ||
| JP2013525444A5 (ja) | ||
| JP2009529541A5 (ja) | ||
| JP2009541216A5 (ja) | ||
| JP2009502743A5 (ja) | ||
| JP2015145426A5 (ja) | ||
| JP2014515351A5 (ja) | ||
| JP2007504174A5 (ja) | ||
| JP2008539267A5 (ja) | ||
| JP2014528901A5 (ja) | ||
| JP2011522816A5 (ja) | ||
| JP2013543896A5 (ja) | ||
| JP2009530288A5 (ja) | ||
| JP2010529118A5 (ja) | ||
| JP2014502641A5 (ja) | ||
| JP2014503593A5 (ja) | ||
| RU2009133262A (ru) | Нападизилатная соль антагониста мускаринового мз-рецептора | |
| JP2013522326A5 (ja) | ||
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| JP2015516419A5 (ja) | ||
| JP2013507408A5 (ja) |